Semaglutide Sales and What They Mean for You

Why semaglutide sales climbed so sharply, and what drove the shift

The scale of semaglutide's commercial rise is not accidental. STEP 1, the pivotal phase-3 trial published in the New England Journal of Medicine, showed an average body-weight reduction of around 15% over 68 weeks at the 2.4mg weekly dose, figures that had not been seen before in a licensed weight-management medicine. Clinicians and patients took note.

That evidence landed in a healthcare landscape where obesity rates were already high and NHS waiting lists were growing. Private demand accelerated first, then NICE recommended Wegovy through specialist services (TA875), and NHS England began phasing in tirzepatide through GP practices from 2025. Each step increased public awareness of GLP-1 medicines broadly, and semaglutide (already well established in diabetes care as Ozempic) was the name many people arrived at first.

The result has been quarterly prescription volumes that Novo Nordisk themselves described as outpacing manufacturing capacity at points in 2023 and 2024. Supply has gradually stabilised, but the context of that demand still matters for anyone looking at their options today, including those exploring how semaglutide is available in Wales, where access pathways have their own distinct considerations. Wegovy's sales trajectory tells much of this story in concrete detail.

The decision most people are actually facing when they search this topic

A question our prescribers hear most weeks runs roughly: "I've seen semaglutide everywhere, is it still worth starting, or has the moment passed?" The honest answer is that the clinical case has only strengthened. NICE recommendations remain in place. The MHRA's approval of a dedicated single-dose 7.2mg Wegovy pen in April 2026 expanded dosing options, with trials reporting around 20.7% average weight loss over 72 weeks at that higher dose. And in June 2026, semaglutide became the first GLP-1 approved as an oral tablet for weight management in the UK, broadening the choice further.

So the decision is less "should I consider semaglutide" and more "which licensed route, through which regulated service, makes clinical and practical sense for me?" That framing matters because it moves the focus to suitability and safety rather than trend-chasing. BMI thresholds, existing health conditions and medication history all feed into whether Wegovy is the right fit, and a prescriber, not a sales figure, is what settles that question.

If cost is part of your thinking, the Wegovy cost page explains what private treatment typically involves and what an all-in price should include.

What rising sales mean for safety and supply chain integrity

High demand for any prescription medicine creates a secondary market for fakes, and semaglutide is no exception. The MHRA has issued multiple public warnings about counterfeit weight-loss pens, including Yellow Card reports from patients who received products that did not contain what was stated on the label. In October 2025, enforcement teams raided the first known illicit UK manufacturing site producing counterfeit tirzepatide pens, and around 20 million doses of illegally traded weight-loss medicines (estimated street value £45m) were seized across 2025 alone.

The pattern with semaglutide fakes is consistent: products sold via social media, messaging apps or websites that do not require a valid prescription before sale. Prices are often significantly below the private market rate. The safe check is simple, verify any online pharmacy on the GPhC register before ordering. A legitimate pharmacy will hold a GPhC premises registration and will require a clinical assessment before supplying a prescription-only medicine.

If you want to understand more about how semaglutide sits within the broader weight-loss medicine landscape, the semaglutide overview covers mechanism, licensed uses and the distinction between Wegovy and Ozempic clearly. For historical context on how the market developed, semaglutide sales in 2024 provides a useful reference point.

Treatment for weight management through nume is available via a free consultation, reviewed the same day by a GPhC-registered prescriber. If semaglutide is clinically suitable, treatment is dispatched the same day for free next-working-day delivery. Start your free consultation to see whether Wegovy is right for you.